American Century Companies Inc. Has $15.38 Million Stock Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

American Century Companies Inc. increased its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 46.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 608,457 shares of the biopharmaceutical company’s stock after purchasing an additional 193,093 shares during the period. American Century Companies Inc. owned approximately 0.92% of Celldex Therapeutics worth $15,376,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the business. EverSource Wealth Advisors LLC boosted its holdings in shares of Celldex Therapeutics by 215.7% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 878 shares in the last quarter. Swiss National Bank boosted its stake in Celldex Therapeutics by 1.2% during the fourth quarter. Swiss National Bank now owns 117,300 shares of the biopharmaceutical company’s stock worth $2,964,000 after acquiring an additional 1,400 shares in the last quarter. KBC Group NV grew its holdings in Celldex Therapeutics by 79.1% in the fourth quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company’s stock worth $94,000 after purchasing an additional 1,647 shares during the period. Teachers Retirement System of The State of Kentucky increased its stake in Celldex Therapeutics by 5.1% in the third quarter. Teachers Retirement System of The State of Kentucky now owns 42,628 shares of the biopharmaceutical company’s stock valued at $1,449,000 after purchasing an additional 2,070 shares in the last quarter. Finally, AlphaQuest LLC raised its holdings in shares of Celldex Therapeutics by 171.0% during the fourth quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company’s stock valued at $108,000 after purchasing an additional 2,705 shares during the period.

Analyst Upgrades and Downgrades

CLDX has been the subject of several research reports. Morgan Stanley started coverage on Celldex Therapeutics in a research note on Thursday, March 20th. They issued an “overweight” rating and a $46.00 target price for the company. HC Wainwright restated a “buy” rating and set a $80.00 price objective on shares of Celldex Therapeutics in a report on Friday, February 28th. The Goldman Sachs Group cut their target price on Celldex Therapeutics from $42.00 to $36.00 and set a “neutral” rating on the stock in a report on Monday, March 3rd. Cantor Fitzgerald restated an “overweight” rating and set a $67.00 price target on shares of Celldex Therapeutics in a research note on Wednesday, January 29th. Finally, UBS Group initiated coverage on shares of Celldex Therapeutics in a research note on Thursday, February 13th. They issued a “buy” rating and a $44.00 price objective on the stock. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $54.33.

Celldex Therapeutics Price Performance

Shares of CLDX stock opened at $18.15 on Tuesday. The firm has a 50-day moving average of $21.78 and a 200-day moving average of $26.06. Celldex Therapeutics, Inc. has a one year low of $17.63 and a one year high of $47.00. The company has a market cap of $1.20 billion, a P/E ratio of -7.06 and a beta of 1.76.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.73) by $0.02. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. The firm had revenue of $1.18 million during the quarter, compared to analyst estimates of $1.25 million. As a group, research analysts expect that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current fiscal year.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.